IP Library Granted Patent US 12,360,350
Granted Patent B2
US 12,360,350 · App. 17/155,585 · Granted Jul 15, 2025

Devices, systems, and methods for otology

Inventors: Eugene de Juan (Brisbane, CA); Hugo Peris (Brisbane, CA); Signe Erickson (Brisbane, CA); Vrad Levering (Brisbane, CA); Nikhil Talreja (Brisbane, CA)
Assignee: Spiral Therapeutics, Inc.
G02B21/0012A61B1/018A61B1/227A61B17/29A61B17/320068A61B17/3205A61B17/3423A61B17/3468A61B17/3478A61B18/04A61B18/1485A61B18/20A61F2/958A61F11/20A61F11/202A61M31/00A61M31/002A61M37/0015G02B21/0032G02B21/22A61B2017/00115A61B2017/00787A61B2017/00867A61B2017/32007A61B2018/00327A61B2217/005A61F2002/183A61F2250/0067A61M2037/0023A61M2037/0046A61M2205/04A61M2210/0662A61M2210/0668
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,360,350
App. No.
17/155,585
Granted
Jul 15, 2025
Kind
B2
Abstract

Devices, systems, and methods can be employed to facilitate performing procedures in the outer, middle, and/or inner ear in order to diagnose and/or treat disorders including, but not limited to, hearing loss and other ear disorders. For example, this document describes devices, systems and methods that include instruments and techniques to minimize the invasiveness and/or to enhance the efficacy of procedures that are performed in the outer, middle, and/or inner ear spaces such as mastoidectomy, tympanoplasty, cholesteatoma treatments, otosclerosis treatments, and Eustachian tube treatments.

Claims (14)

1. A method for treating cholesteatoma in a middle ear, the method comprising:

advancing, via an outer ear canal and a trans-tympanic membrane approach into the middle ear, a shaft of an instrument through a lumen in the tympanic membrane having an access diameter of 0.5 mm to 1.0 mm such that a distal tip of the instrument comes into contact with the cholesteatoma in the middle ear at a location spaced posteriorly away from a Eustachian tube, wherein the instrument is configured to provide a combination of injection and ultrasound emulsification;

while at least a portion of the shaft of the instrument is positioned in the lumen in the tympanic membrane having the access diameter of 0.5 mm to 1.0 mm, delivering a therapeutic treatment that includes both a therapeutic agent injection and ultrasound emulsification from the distal tip of the instrument to the cholesteatoma to debulk the cholesteatoma via the trans-tympanic membrane approach at a first time; and

after said delivering the therapeutic treatment that includes both the therapeutic agent injection and ultrasound emulsification to debulk the cholesteatoma at the first time, advancing at a second later time, a subsequent instrument through a subsequent lumen in the tympanic membrane having an access diameter of 0.5 mm to 1.0 mm such that a distal tip of the subsequent instrument comes into contact with a regrowth of the cholesteatoma in the middle ear at the location spaced posteriorly away from the Eustachian tube; and

while at least a portion of the shaft of the subsequent instrument is positioned in the subsequent lumen in the tympanic membrane having the access diameter of 0.5 mm to 1.0 mm, delivering a subsequent therapeutic treatment that includes both a subsequent therapeutic agent injection and ultrasound emulsification from the distal tip of the subsequent instrument to the cholesteatoma to debulk the cholesteatoma via the trans-tympanic membrane approach at the second later time.

2. The method of claim 1 , wherein the advancing at said first time comprises moving the shaft of the instrument through a perforation in the tympanic membrane.

3. The method of claim 2 , further comprising placing a port device in the perforation in the tympanic membrane such that the port device defines the access diameter of 0.5 mm to 1.0 mm.

4. The method of claim 1 , wherein the shaft of the instrument at the first time is configured to advance through the lumen in the tympanic membrane having the access diameter of 0.5 mm to 1.0 mm and comprises a steerable or deflectable shaft.

5. The method of claim 4 , wherein the therapeutic agent injected into the cholesteatoma at the first time via the trans-tympanic membrane approach comprises a sustained release formulation.

6. The method of claim 5 , wherein the therapeutic agent injected into the cholesteatoma at the first time via the trans-tympanic membrane approach comprises a keratolytic agent, an immune response modifier, or a cryotherapy agent.

7. The method of claim 6 , wherein the therapeutic agent injected into the cholesteatoma at the first time via the trans-tympanic membrane approach is administered in combination with said ultrasound emulsification for tissue removal in the middle ear.

8. The method of claim 4 , wherein said delivering the subsequent therapeutic treatment that includes both the subsequent therapeutic agent injection and ultrasound emulsification at the second later time is one or more years after the first time.

9. The method of claim 1 , wherein the instrument is configured to provide a combination of endoscopy, injection, and ultrasound emulsification.

10. The method of claim 1 , further comprising providing visual confirmation of the cholesteatoma in the middle ear prior to patient reported symptoms.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2021
From: JUAN, EUGENE DE; ERICKSON, SIGNE; LIMB, CHARLES; LEVERING, VRAD
To: SPIRAL THERAPEUTICS INC.
Reel/Frame 055458/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2021
From: JUAN, EUGENE DE; ERICKSON, SIGNE; LEVERING, VRAD
To: SPIRAL THERAPEUTICS INC.
Reel/Frame 055458/0419 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2021
From: JUAN, EUGENE DE; PERIS, HUGO; ERICKSON, SIGNE; LEVERING, VRAD; TALREJA, NIKHIL
To: SPIRAL THERAPEUTICS INC.
Reel/Frame 055458/0476 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2021
From: JUAN, EUGENE DE; ERICKSON, SIGNE; LIMB, CHARLES; PERIS, HUGO; TALREJA, NIKHIL; AYOOB, ANDREW; LEVERING, VRAD
To: SPIRAL THERAPEUTICS INC.
Reel/Frame 055458/0217 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2021
From: JUAN, EUGENE DE; ERICKSON, SIGNE; LIMB, CHARLES; PERIS, HUGO; TALREJA, NIKHIL; AYOOB, ANDREW; LEVERING, VRAD
To: SPIRAL THERAPEUTICS INC.
Reel/Frame 055458/0278 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2021
From: JUAN, EUGENE DE; ERICKSON, SIGNE; LIMB, CHARLES; PERIS, HUGO; TALREJA, NIKHIL; AYOOB, ANDREW
To: SPIRAL THERAPEUTICS INC.
Reel/Frame 055458/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2021
From: JUAN, EUGENE DE; PERIS, HUGO; ERICKSON, SIGNE; LEVERING, VRAD
To: SPIRAL THERAPEUTICS INC.
Reel/Frame 055458/0608 →
Continuity (10)
Provisional Application 63082996 · Sep 24, 2020
Provisional Application 63081015 · Sep 21, 2020
Provisional Application 63080510 · Sep 18, 2020
Provisional Application 63078141 · Sep 14, 2020
Provisional Application 63077448 · Sep 11, 2020
Provisional Application 63051568 · Jul 14, 2020
Provisional Application 63040495 · Jun 17, 2020
Provisional Application 63024183 · May 13, 2020
Provisional Application 62965481 · Jan 24, 2020
Related Publication 20210228412A1 · Jul 29, 2021
References Cited (49)
US 5421818A · Arenberg · 1995 [cited by applicant]
US 5707383A · Bays et al. · 1998 [cited by applicant]
US 5849008A · Anthony · 1998 [cited by applicant]
US 6024726A · Hill · 2000 [cited by applicant]
US 6045528A · Arenberg et al. · 2000 [cited by applicant]
US 6093150A · Chandler · 2000 [cited by examiner]
US 6120484A · Silverstein · 2000 [cited by applicant]
US 6440102B1 · Arenberg et al. · 2002 [cited by applicant]
US 6475138B1 · Schechter · 2002 [cited by examiner]
US 6648873B2 · Arenberg et al. · 2003 [cited by applicant]
US 7351246B2 · Epley · 2008 [cited by applicant]
US 7704259B2 · Kaplan et al. · 2010 [cited by applicant]
US 8197461B1 · Arenberg et al. · 2012 [cited by applicant]
US 9352084B2 · Decker et al. · 2016 [cited by applicant]
US 9616207B2 · Verhoeven · 2017 [cited by applicant]
US 10130514B2 · Imran et al. · 2018 [cited by applicant]
US 20030220536A1 · Hissong · 2003 [cited by applicant]
US 20040172005A1 · Arenberg et al. · 2004 [cited by applicant]
US 20050182385A1 · Epley · 2005 [cited by examiner]
US 20070264296A1 · Myntti · 2007 [cited by applicant]
US 20080154343A1 · Li · 2008 [cited by examiner]
US 20110224629A1 · Jolly et al. · 2011 [cited by applicant]
US 20130211438A1 · Dubois et al. · 2013 [cited by applicant]
US 20130245569A1 · Jolly et al. · 2013 [cited by applicant]
US 20130274715A1 · Chan et al. · 2013 [cited by applicant]
US 20150151095A1 · Tarabichi · 2015 [cited by examiner]
US 20160346511A1 · Cohen et al. · 2016 [cited by applicant]
US 20170071509A1 · Pandey · 2017 [cited by examiner]
US 20170172804A1 · Watanabe et al. · 2017 [cited by applicant]
US 20170252089A1 · Hester et al. · 2017 [cited by applicant]
US 20190015254A1 · Bendory et al. · 2019 [cited by applicant]
US 20190321610A1 · Goldfarb et al. · 2019 [cited by applicant]
US 20190321611A1 · Sacherman et al. · 2019 [cited by applicant]
US 20200094030A1 · Kim et al. · 2020 [cited by applicant]
US 20210128457A1 · Liao · 2021 [cited by examiner]
JP 2001508033A · 2001 [cited by applicant]
JP 2009536666A · 2009 [cited by applicant]
JP 2015109990A · 2015 [cited by applicant]
WO WO2007134055A1 · 2007 [cited by applicant]
WO WO2008097317 · 2008 [cited by applicant]
WO WO2019152866 · 2019 [cited by applicant]
WO WO2019200529 · 2019 [cited by applicant]
WO WO2019200259A1 · 2019 [cited by examiner]
WO WO2020115674 · 2020 [cited by applicant]
Smooth muscle in the annulus fibrosus of the tympanic membrane in bats, rodents, insectivores, and humans (Year: 2005). [cited by examiner]
Cholesteatoma in children, predictors and calculation of recurrence rates (Year: 1999). [cited by examiner]
Neuroradiology of Cholesteatomas (Year: 2011). [cited by examiner]
International Search Report and Written Opinion in International Appln. No. PCT/US2021/14610, dated Jun. 30, 2021, 11 pages. [cited by applicant]
Extended European Search Report in European Appln No. 21744191.4, dated Jan. 23, 2024, 8 pages. [cited by applicant]